Global Biologics Outsourcing Market Analysis 2025–2029: Opportunities for Strategic Growth

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Was The Biologics Outsourcing Market Worth In 2025, And What Is Its Anticipated Value By 2029?

The biologics outsourcing market has experienced rapid expansion in recent years. This market is projected to expand from $20.06 billion in 2024 to $22.58 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 12.6%. Historically, this growth has been driven by factors such as escalating R&D expenditures, intensified regulatory demands, the need for specialized knowledge, and increasing globalization.

The biologics outsourcing market is anticipated to experience substantial growth over the next few years. It is projected to expand to $37.28 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 13.4%. This expansion during the forecast period is primarily driven by the growth of emerging markets, the rise of personalized medicine, the formation of strategic alliances, and the expiration of patents for biological drugs. Significant trends expected during this period include technological advancements, increasing complexity in outsourcing, the expansion of the biosimilars market, the integration of data analytics, and improvements in supply chain resilience.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12573&type=smp

Which Factors And Drivers Are Influencing The Biologics Outsourcing Market In 2025?

The increasing prevalence of cancer cases is projected to drive the expansion of the biologics outsourcing market moving forward. Cancer refers to a wide array of illnesses that can emerge in virtually any organ or tissue within the body when abnormal cells multiply without control, breach their usual limits, and either metastasize to other organs or infiltrate adjacent body parts. Biologics outsourcing plays a significant role in addressing cancer cases by offering specialized expertise, resources, and infrastructure for the development, manufacturing, and clinical supply of biologic therapies. These therapies include monoclonal antibodies, immunotherapies, and other targeted biologics used in the diagnosis, treatment, and management of various cancer types. For instance, in January 2023, the National Center for Biotechnology Information, a US-based intergovernmental organization, reported 1,958,310 new cancer cases in the United States, with 609,820 cancer deaths anticipated for 2023. Furthermore, by 2040, the yearly number of new cancer cases is expected to climb to 29.5 million, and cancer-related deaths are projected to reach 16.4 million. Therefore, the rising number of cancer cases is a key driver for the growth of the biologics outsourcing market.

How Is The Biologics Outsourcing Market Classified Into Different Segments?

The biologics outsourcingmarket covered in this report is segmented –

1) By Product Type: Antibodies; Recombinant; Vaccines; Protein; Other Products

2) By Source: Human; Microbial; Other Source

3) By Application: Oncology; Cellular And Gene Therapy; Blood And Blood-Related Products Development; Vaccine Development; Stem Cell Research; Other Applications

4) By End User: Pharmaceutical Industries; Biotechnology Industries; Contract Development And Manufacturing Organization(CDMO)

Subsegments:

1) By Antibodies: Monoclonal Antibodies; Polyclonal Antibodies

2) By Recombinant: Recombinant Proteins; Recombinant DNA Products

3) By Vaccines: Therapeutic Vaccines; Preventive Vaccines

4) By Protein: Enzymes; Hormones; Cytokines

5) By Other Products: Gene Therapies; Cell Therapies; Biosimilars

How Are Emerging Market Trends Shaping The Biologics Outsourcing Industry Landscape?

Advancements in biologics represent a significant trend gaining traction within the biologics outsourcing market. Major corporations active in this market are embracing new technologies to maintain their market position. For example, in February 2022, Abzena, a US-based contract development and manufacturing organization (CDMO), Alira Health, a US-based healthcare firm, and Oncodesign, a France-based biopharmaceutical company, launched DRIVE-Biologics, a consortium dedicated to biologic drug discovery and development programs. This initiative delivers integrated solutions with specialized services, spanning from biological discovery to clinical and commercial manufacturing. This partnership, which merges industry leadership in areas such as design and developability, preclinical pharmacology and pharmaco-imaging proof of concept, toxicology, and clinical design through commercial manufacturing, aims to streamline information exchange and program deliverables to mitigate risks in biologics development. Additionally, partners will have access to expertise throughout all stages of drug discovery and development, including design, preclinical, clinical, and CMC (chemistry, manufacturing, and control).

Who Are The Major Companies Operating In The Biologics Outsourcing Market?

Major companies operating in the biologics outsourcing market include AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim GmbH, Lonza Group Ag, Catalent Inc., Sartorius Stedim Biotech S.A., Charles River Laboratories International Inc., WuXi Biologics Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., CordenPharma GmbH, Ajinomoto Bio-Pharma Services, Syngene International Limited, Rentschler Biopharma SE, Albany Molecular Research Inc., KBI Biopharma Inc., Fujifilm Diosynth Biotechnologies Inc., Avid Bioservices Inc., BioVectra Inc., ProBioGen AG, ABL Inc., Vibalogics GmbH, JHL Biotech Inc., Goodwin Biotechnology Inc., Crown Bioscience Inc., Cytovance Biologics Inc., LakePharma Inc., AGC Biologics GmbH, Biomay AG, Polpharma Biologics S.A.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

Which Regional Markets Are Contributing Most To The Biologics Outsourcing Industry Expansion?

North America was the largest region in the biologics outsourcing market in 2024. The regions covered in the biologics outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Biologics Outsourcing Market Report:

https://www.thebusinessresearchcompany.com/customise?id=12573&type=smp

Browse Through More Reports Similar to the Global Biologics Outsourcing Market 2025, By The Business Research Company

Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biologics-global-market-report

Biologics Contract Development Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

Biologics Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795